Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CDC25A | P30304 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28240062 | 0.76 | KMT2A (0.38) | MEN1KMT2ACDC25ACDC25BACHE | |
| SCHEMBL28892077 | 0.76 | CDC25A (0.36) | MEN1KMT2ACDC25ACDC25BACHE | |
| SCHEMBL29131402 | 0.76 | ALDH1A1 (0.46) | MEN1KMT2ACDC25ACDC25BMAPT | |
| SCHEMBL8894500 | 0.74 | ALDH1A1 (0.36) | MEN1KMT2APOLBS100A4LMNA | |
| SCHEMBL677629 | 0.73 | MEN1 (0.55) | MEN1KMT2ACDC25BACHEMAPT | |
| SCHEMBL27947998 | 0.72 | CDC25B (0.40) | MEN1KMT2ACDC25ACDC25BMAPT | |
| SCHEMBL12646072 | 0.71 | MEN1 (0.52) | MEN1KMT2ACDC25BACHEMAPT | |
| SCHEMBL9205811 | 0.71 | BRD4 (0.50) | MEN1KMT2AACHEMAPTPOLB | |
| SCHEMBL29458545 | 0.70 | DRD2 (0.41) | ACHECYP19A1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL251288 | 0.70 | DRD2 (0.41) | ACHECYP19A1LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555552-A | Aldehyde compound, process for producing the same, and perfume composition | 三菱瓦斯化学株式会社 | 2022-05-27 | — | — | CN | disclosed |
| CN-108676624-B | Extraction method of rose essential oil and rose essential oil | 高延厅 | 2022-02-11 | — | — | CN | disclosed |
| CN-108676624-A | The extracting method and Rosa Damascana of Rosa Damascana | 高延厅 | 2018-10-19 | — | — | CN | disclosed |
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | disclosed |
| EP-0948478-A1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO 1,2-g]-CHROM-3-ENE, BENZO 1,2-g]-THIOCHROM-3-ENE AND BENZO 1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998025875-A1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5741896-A | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1997048672-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | CHAT, DLAT, CPT1A | MEN1 1178/4885KMT2A 3695/4885CDC25A 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.